<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cuban de Med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232023000100016</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La semaglutida en el tratamiento de las personas con diabesidad]]></article-title>
<article-title xml:lang="en"><![CDATA[Semaglutide in the Treatment of Diabesity Individuals]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[José Hernández]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Endocrinología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<volume>62</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232023000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232023000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232023000100016&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La semaglutida es un fármaco que contribuye a la liberación de insulina por el páncreas y a la supresión del apetito por lo que lo convierte en un importante candidato para ser usado en el tratamiento de la diabesidad.  Objetivo:  Describir el efecto de la semaglutida en el tratamiento de las personas con diabesidad.  Métodos:  Se revisó la literatura publicada en el período comprendido de enero-febrero de 2021. Las palabras clave utilizadas fueron obesidad; diabetes mellitus; diabesidad; semaglutida; análogo del péptido similar al glucagón tipo 1. Se utilizaron como motores de búsqueda las bases de datos de Google Académico, PubMed y SciELO. Se evaluaron diferentes trabajos de revisión, investigación y páginas web que tenían menos de 10 años de publicados en idioma español, portugués o inglés, y que por el título trataban el tema de estudio. Fueron excluidos los artículos que no abordaron la relación entre diabetes y obesidad, así como el tratamiento con análogos del péptido similar al glucagón tipo 1. Esto permitió la consulta de 84 artículos, de los cuales 59 fueron referenciados.  Conclusiones:  El empleo de semaglutida favorece una mejor evolución en paciente con diabesidad, como complemento de una dieta y una actividad física adecuada. Al optimizar el control glucémico, contribuir a la pérdida de peso y a la mejoraría de ciertas comorbilidades, entre ellas la salud cardiovascular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Semaglutide is a drug that contributes to the release of insulin from the pancreas and suppresses appetite, which makes it an important candidate for treating diabesity.  Objective:  To describe the role of semaglutide in the treatment of diabesity individuals.  Methods:  The necessary information to write this article was obtained in the 2022 two-month period January-February. The keywords used were obesity; Mellitus diabetes; diabesity; semaglutide; type 1 glucagon-like peptide analogue. The search engines corresponding to the Google Scholar, PubMed and SciElO databases were used. Different review, research and web pages were evaluated, which in general were published no more than 10 years ago, in Spanish, Portuguese or English and which dealt with the subject of study by title. Articles that did not address the relationship between diabetes and obesity, as well as treatment with glucagon-like peptide 1 analogues, were excluded. This allowed the consultation of 84 articles, 59 of them were referenced.  Conclusions:  The use of semaglutide, as a complement to a diet and physical activity appropriate to the needs of patients with diabesity, brought about several effects that favor better evolution of this health problem, by optimizing glycemic control, contributing to the loss of weight and the improvement of certain comorbidities, including cardiovascular health.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[obesidad]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus]]></kwd>
<kwd lng="es"><![CDATA[diabesidad]]></kwd>
<kwd lng="es"><![CDATA[semaglutida]]></kwd>
<kwd lng="es"><![CDATA[análogo del péptido similar al glucagón tipo 1]]></kwd>
<kwd lng="en"><![CDATA[obesity]]></kwd>
<kwd lng="en"><![CDATA[mellitus diabetes]]></kwd>
<kwd lng="en"><![CDATA[diabesity]]></kwd>
<kwd lng="en"><![CDATA[semaglutide]]></kwd>
<kwd lng="en"><![CDATA[glucagon-like peptide type 1 analog]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Colamarco]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Rivadeneira]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos generales sobre la diabesidad: fisiopatología y tratamiento]]></article-title>
<source><![CDATA[Rev Cuban Endocrinol]]></source>
<year>2021</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riobó]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pautas dietéticas en la diabetes y en la obesidad]]></article-title>
<source><![CDATA[Nutrición Hospitalaria]]></source>
<year>2018</year>
<volume>35</volume>
<numero>SPE4</numero>
<issue>SPE4</issue>
<page-range>109-15</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[JCK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diabesity epidemic in the light of evolution: insights from the capacity-load model]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2019</year>
<volume>62</volume>
<page-range>1740-50</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[ACT]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Borlaug]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging]]></article-title>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2020</year>
<volume>18</volume>
<page-range>291-304</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grosso]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Wassermann]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
</person-group>
<source><![CDATA[Obesidad y riesgo cardiometabólico, 7° Curso de Capacitación de Posgrado a Distancia Síndrome Metabólico y Riesgo Vascular FEPREVA]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabesidad. Visión de su futuro]]></article-title>
<source><![CDATA[Actualidad en diabetes]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kow]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sharaiha]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Toouli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Obesidad: una pandemia en curso]]></source>
<year>2021</year>
<publisher-name><![CDATA[Copresidentes de la Organización Mundial de Gastroenterología (WGO)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>Ministerio de Salud. Dirección Nacional de Abordaje Integral de Enfermedades No Transmisibles</collab>
<source><![CDATA[Guía de Práctica Clínica Nacional sobre Prevención, Diagnóstico y Tratamiento de la Diabetes Mellitus Tipo 2 (DM2)]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Standards of Medical Care in Diabetes-2020 Abridged for Primary Care Providers]]></article-title>
<source><![CDATA[Clin Diabetes]]></source>
<year>2020</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-38</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia Edición 2019]]></article-title>
<source><![CDATA[Revista ALAD]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosentino]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grant P]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>255-323</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[De Regules]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pardinas]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualidades en el tratamiento farmacológico a largo plazo de la obesidad. ¿Una opción terapéutica?]]></article-title>
<source><![CDATA[Med In Mex]]></source>
<year>2018</year>
<volume>34</volume>
<page-range>946-58</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profundizando en la eficacia y seguridad de un nuevo antidiabético: la semaglutida subcutánea]]></article-title>
<source><![CDATA[Hoja de Evaluación de Medicamentos de Castilla-La Mancha]]></source>
<year>2021</year>
<volume>XXII</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[dos Santos]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La atención farmacéutica en la evaluación de la seguridad y eficacia del uso off-label de dulaglutida en el tratamiento del sobrepeso y la obesidad]]></article-title>
<source><![CDATA[Revista Saúde em Foco]]></source>
<year>2018</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weeda]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Muraoka]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Brock]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes A meta-analysis]]></article-title>
<source><![CDATA[International Journal of Clinical Practice]]></source>
<year>2021</year>
<volume>75</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trujillo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Goldman]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes]]></article-title>
<collab>J</collab>
<source><![CDATA[Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy]]></source>
<year>2017</year>
<volume>37</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>927-43</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orozco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas opciones farmacológicas para el tratamiento de la diabetes tipo 2]]></article-title>
<source><![CDATA[Revista Clínica de Medicina de Familia]]></source>
<year>2018</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>122-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gribble]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Reimann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enteroendocrine Cells Chemosensors in the Intestinal Epithelium]]></article-title>
<source><![CDATA[Annual Review of Physiology]]></source>
<year>2016</year>
<volume>78</volume>
<page-range>277-99</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbañil]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipoglucemiantes orales en el tratamiento actual de la Diabetes Mellitus tipo 2]]></article-title>
<source><![CDATA[Diagnóstico]]></source>
<year>2020</year>
<volume>59</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Mecanismo de acción de los péptidos insulinotrópico GIP y GLP-1 (incretinas): papel desempeñado en la diabetes]]></source>
<year>2018</year>
<publisher-name><![CDATA[Facultad de Farmacia, Universidad Complutense]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobre el tratamiento farmacológico de la Diabetes mellitus]]></article-title>
<source><![CDATA[Revista Cubana de Alimentación y Nutrición]]></source>
<year>2020</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>S99-S111</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Mecanismo de acción de las incretinas papel desempeñado en diabesidad]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barros]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[dos Reis Meirelles]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Terra]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ação da Incretina GLP-1 e Perspectivas para a Redução da Incidência da Obesidade]]></article-title>
<source><![CDATA[Revista Transformar]]></source>
<year>2021</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>483-97</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carpio]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Duran]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rodas]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Abad]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapia incretinomimética: evidencia clínica de la eficacia de los agonistas del GLP-1R y sus efectos cardio-protectores]]></article-title>
<source><![CDATA[Revista Latinoamericana de Hipertensión]]></source>
<year>2018</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>400-15</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muskiet]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Tonneijck]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Smits]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Van Baar]]></surname>
<given-names><![CDATA[MJB]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[MHH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes]]></article-title>
<source><![CDATA[Nature Reviews Nephrology]]></source>
<year>2017</year>
<volume>13</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>605-28</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jackuliak]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ku&#382;ma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Payer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of antidiabetic treatment on bone]]></article-title>
<source><![CDATA[Physiol Res]]></source>
<year>2019</year>
<volume>68</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S107-S20</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montes]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparación de péptidos intestinales en mujeres postmenopáusicas con y sin osteoporosis: estudio de casos y controles]]></source>
<year>2020</year>
<publisher-name><![CDATA[Universidad de Jaén. Departamento de Ciencias de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Céspedes]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ardevol]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las incretinas como nueva opción terapéutica en la diabetes mellitus tipo 2]]></article-title>
<source><![CDATA[Rev Cuban Med]]></source>
<year>2015</year>
<volume>54</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-66</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fontalvo]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Daza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Raad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pájaro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Villacob]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Agonistas del receptor Glp-1: Desde su efecto fisiológico en el sistema incretina hasta du rol en enfermedad renal diabética]]></article-title>
<source><![CDATA[Archivos de medicina]]></source>
<year>2021</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>2-12</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tucker]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La FDA aprueba la semaglutida para la diabetes tipo 2]]></article-title>
<source><![CDATA[Medscape]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tucker]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La FDA aprueba el agonista oral de GLP-1 'Game-Changer' para la diabetes tipo 2]]></article-title>
<source><![CDATA[Medscape]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="">
<collab>Administración de Alimentos y Medicamentos de los Estados Unidos (FDA)</collab>
<source><![CDATA[La FDA aprueba un nuevo tratamiento farmacológico para el control de peso crónico, el primero desde 2014]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="">
<collab>VADEMECUM</collab>
<source><![CDATA[Semaglutida]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Spain ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="book">
<source><![CDATA[Semaglutida (Rx). Medicamentos y enfermedades]]></source>
<year>2022</year>
<publisher-name><![CDATA[Medscape]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Ficha técnica Ozempic 0,25 mg solución inyectable en pluma precargada]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Ficha técnica Rybelus 7 mg comprimidos]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Anexo I. Ficha técnica o resumen de características del producto (Ozempic)]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Anexo I. Ficha técnica o resumen de características del producto (Rybelsus)]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica o resumen de características del producto (Wegovy)]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blundell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Finlayson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Axelsen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Flint]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbons]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kvist]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity]]></article-title>
<source><![CDATA[Diabetes, Obesity and Metabolism]]></source>
<year>2017</year>
<volume>19</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1242-51</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Batterham]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Calanna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Van Gaal]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Once-weekly semaglutide in adults with overweight or obesity]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>989-1002</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Færch]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jeppesen]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
<name>
<surname><![CDATA[Pakseresht]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[Sue D]]></given-names>
</name>
<name>
<surname><![CDATA[Perreault]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10278</numero>
<issue>10278</issue>
<page-range>971-84</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodbard]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Dougherty]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Taddei-Allen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care]]></article-title>
<source><![CDATA[The American Journal of Managed Care]]></source>
<year>2020</year>
<volume>26</volume>
<numero>16^sSuppl</numero>
<issue>16^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>S335-43</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="book">
<source><![CDATA[Programa d'Harmonització Farmacoterapèutica. Semaglutida oral per al tractament de la diabetis mellitus tipus 2]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Servei Català de la Salut]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Husain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Birkenfeld]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Donsmark]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dungan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Eliaschewitz]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2019</year>
<volume>381</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>841-51</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahrén]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Atkin]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Charpentier]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Birch]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials]]></article-title>
<source><![CDATA[Diabetes, Obesity and Metabolism]]></source>
<year>2018</year>
<volume>20</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2210-9</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marso]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Consoli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eliaschewitz]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Jódar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>1834-44</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Hramiak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Jódar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Madsbad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gondolf]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial]]></article-title>
<source><![CDATA[Cardiovascular diabetology]]></source>
<year>2019</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fainberg]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Husain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ripa]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2021</year>
<volume>23</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1677-80</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Colhoun]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Dagenais]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lakshmanan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pais]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2019</year>
<volume>394</volume>
<numero>10193</numero>
<issue>10193</issue>
<page-range>121-30</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jendle]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Birkenfeld]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Polonsky]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Silver]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Uusinarkaus]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2019</year>
<volume>21</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2315-26</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jódar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Michelsen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Polonsky]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Réa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sandberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vilsbøll]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2020</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1339-47</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giménez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Piskorz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Demaría]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Nanfara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzatti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zapata]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toma de posición sobre los agonistas del receptor de GLP-1]]></article-title>
<source><![CDATA[Revista de la Federación Argentina de Cardiología]]></source>
<year>2021</year>
<volume>50</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>4-10</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilsbøll]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Simó]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy]]></article-title>
<source><![CDATA[Diabetes, Obesity and Metabolism]]></source>
<year>2018</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>889-97</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<collab>SESCA</collab>
<article-title xml:lang=""><![CDATA[Profundizando en la eficacia, seguridad y eficiencia de un nuevo antidiabético: la semaglutida subcutánea]]></article-title>
<source><![CDATA[Hoja de Evaluación de Medicamentos de Castilla-La Mancha]]></source>
<year>2020</year>
<volume>XXII</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Builes]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<source><![CDATA[Individualización del tratamiento. XVIII Memorias Curso de Actualización en Medicina Interna]]></source>
<year>2018</year>
<page-range>142-51</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brody]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los médicos hablan de un medicamento 'revolucionario' para bajar de peso]]></article-title>
<source><![CDATA[AARP]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miramontes]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los arglp-1: una oportunidad para el tratamiento del riesgo cardiometabólico]]></article-title>
<source><![CDATA[Cuadernos de la redGDP]]></source>
<year>2020</year>
<page-range>19-24</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tejera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análogos de GLP-1 en diabetes tipo 2. ¿Cuándo utilizarlos y en qué tipo de pacientes?]]></article-title>
<source><![CDATA[Diabetes (Sociedad Española de Diabetes)]]></source>
<year>2022</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
